Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inion eyes $2m for licensing non-core orthobiologics tech

This article was originally published in Clinica

Executive Summary

Anglo-Finnish developer of orthopaedic implants Inion is to gain up to $2m for licensing a non-core bioactive bone growth technology to US company Curative Biosciences. AIM-listed Inion said it had discovered the bioactive properties of N,N-dimethylacetamide (DMA) in promoting bone repair and regrowth throughresearch carried out at its former Cambridge R&D facility. The technology will be licensed for use either alone as a bioactive agent or in resorbable polymer implants, such as plates, membrane and screws. In addition to the $2m in licensing fees and development and sales milestones, Waltham, Massachusetts-based Curative will pay Inion royalties on revenues generated from any products based on this technology.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041295

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel